Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Akshay Sudhindra"'
Autor:
Matthew E. Stokes, Kerstin Wenzl, C. Chris Huang, María Ortiz, Chih-Chao Hsu, Matthew J. Maurer, Nicholas Stong, Yumi Nakayama, Lei Wu, Hsiling Chiu, Ann Polonskaia, Samuel A. Danziger, Fadi Towfic, Joel Parker, Rebecca L. King, Brian K. Link, Susan L. Slager, Vivekananda Sarangi, Yan W. Asmann, Joseph P. Novak, Akshay Sudhindra, Stephen M. Ansell, Thomas M. Habermann, Patrick R. Hagner, Grzegorz S. Nowakowski, James R. Cerhan, Anne J. Novak, Anita K. Gandhi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Immunochemotherapy has been the mainstay of treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL) yet is inadequate for many patients. In this work, we perform unsupervised clustering on transcriptomic features from a large c
Externí odkaz:
https://doaj.org/article/4dae5fe5634e4259b6d610f0ad207e8d
Autor:
Steve Kanters, Graeme Ball, Brad Kahl, Adriana Wiesinger, Eve H. Limbrick-Oldfield, Akshay Sudhindra, Julia Thornton Snider, Anik R. Patel
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Patients with follicular lymphoma (FL) can have high response rates to early lines of treatment. However, among FL patients relapsed/refractory (r/r) after ≥2 prior lines of therapy (LOT), remission tends to be shorter and there
Externí odkaz:
https://doaj.org/article/923b9b42936e48caa74f6508905b31ed
Autor:
Matthew E Stokes, Kerstin Wenzl, C. Chris Huang, Maria Ortiz Estevez, Matthew J. Maurer, Nicholas Stong, Patrick Hagner, Yumi Nakayama, Chih-Chao Hsu, Samuel A Danziger, Fadi Towfic, Rebecca L. King, Joel S. Parker, Brian K. Link, Susan L. Slager, Vivekananda Sarangi, Yan Asmann, Joseph P. Novak, Akshay Sudhindra, Stephen M. Ansell, Thomas M. Habermann, Grzegorz S. Nowakowski, James R. Cerhan, Anne J. Novak, Anita K. Gandhi
Publikováno v:
Blood. 140:3548-3550
Autor:
John Radford, Steve Kanters, H. Dong, Anik R. Patel, Akshay Sudhindra, Sabela Bobillo, Maria Lia Palomba, L. Ma, John G. Gribben, Kevin Deighton, J. Thornton Snider, Hervé Ghesquières, Paola Ghione, Y. Yang, Sally W. Wade, M. T. Riberio, E. H. Limbrick-Oldfield
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Mount Sinai Expert Guides. :354-363
Autor:
Diem Le, Teresa Ta, Erika Cavallone, Joseph Tuscano, Swetha Kambhampati, Charalambos Andreadis, Matthew J. Wieduwilt, Michelle Padilla, Weiyun Z. Ai, Jesika Reiner, Miguel Castillo, Erika Crawford, Lawrence D. Kaplan, Bita Fakhri, Akshay Sudhindra, Michelle Martinelli, Charlie Aoun
Publikováno v:
Clinical lymphoma, myelomaleukemia. 21(3)
Introduction We designed a multicenter, phase Ib dose-escalation trial of carfilzomib with bendamustine and rituximab in patients with relapsed/refractory non-Hodgkin lymphoma ( NCT02187133 ) in order to improve the response rates of this difficult-t
Autor:
Anik R. Patel, E. H. Limbrick-Oldfield, A Wiesinger, Brad S. Kahl, Akshay Sudhindra, Steve Kanters, B Gurung, J. Thornton Snider
Publikováno v:
Journal of Clinical Oncology. 39:e19548-e19548
e19548 Background: Patients with follicular lymphoma (FL) can have high response rates to early lines of treatment. However, among FL patients relapsed/refractory (r/r) after ≥2 prior lines of therapies (LOT), remission tends to be shorter and ther
Autor:
Matthew J. Wieduwilt, Weiyun Z. Ai, Teresa Ta, Bita Fakhri, Erika Crawford, Lawrence D. Kaplan, Swetha Kambhampati, Diem Le, Michelle Padilla, Charalambos Andreadis, Jimmy Hwang, Joseph Tuscano, Charlie Aoun, Akshay Sudhindra, Jesika Reiner, Michelle Martinelli
Publikováno v:
Blood. 134:2828-2828
Background Despite advances in therapy, relapsed or refractory (RR) non-Hodgkin lymphoma (NHL) remains a major treatment challenge. Preclinical data support the activity of proteasome inhibitors against lymphoma through multiple mechanisms including
Publikováno v:
Blood. 132:5840-5840
Introduction: Post-transplant lymphoproliferative disorder (PTLD) is a heterogenous disease that can develop after solid organ or allogeneic hemopoietic stem cell transplant (HCT). PTLD after HCT is primarily of the monomorphic subtype and driven by
Publikováno v:
Clinical Lung Cancer. 12:360-368
In lung cancer, the introduction of targeted agents in those patients who carry a genetic abnormality has resulted in better clinical outcomes with better quality of life. These molecular abnormalities have also become predictive biomarkers. It is im